Merck to sell its pharma business for $1 billion

Zaire is the most lucrative African country for pharmaceutical companies, with annual sales exceeding $1.2 billion.

That’s up from $500 million in 2011.

Zaire’s pharmaceutical industry has grown so fast in recent years that it now employs nearly 2,000 people, more than in any other African country.

The country also has the second-highest number of patents in the world, after the US.

Merck, the world’s largest pharmaceutical company, is one of the worlds biggest producers of medications for the treatment of cancer, Alzheimer’s, diabetes, and rheumatoid arthritis.

In January, it announced a deal with another African country, South Africa, to buy its pharmaceutical business.

But in a move that could change Zaire forever, the Zaire government said it would sell the country’s pharmaceutical business, and its entire pharmaceutical industry, for $50 billion.

This news could affect the countrys economic future.

“Zaire’s pharma sector is one that has proven to be a key driver of the economy in terms of both exports and domestic demand,” said Jonathan Aker, a senior research fellow at the African Centre for Strategic and International Studies in Johannesburg.

“It’s a very significant sector and it’s a huge export and domestic market.

But as the government says, the government is going to do its best to help it grow and be a part of the market, which could include the acquisition of Merck’s pharmaceutical arm.”

Merck is one the largest pharmaceutical companies in Africa.

The company sells products for more than 80 different diseases and has sold billions of dollars worth of drugs in the region.

But its drugs are made from a variety of chemicals, and many of them have been used in cancer treatments, for instance, the use of carboplatin in chemotherapy.

Zaira Mwahir, a professor at the University of Zaire, said that as Merck would be selling its entire pharma company, it would “have to give up a lot of profits to make the transaction.”

Merk is one other pharmaceutical company that has recently announced a plan to buy Merck.

But it is the largest single buyer of Merks pharmaceutical arm.

Merk already owns a large part of Mercks pharmaceutical arm, including patents, intellectual property, and distribution rights.

The deal would allow Merck more control over its own business and the pharmaceutical sector in Zaire.

“There are a lot more options for acquiring Merck than they have in the past,” Mwahair said.

“They’ve seen the company’s growth, and they want to take a position in the market.”

Zairaw said that Zaire could become a hub for African drug companies, because of its large market.

“The government’s plan to sell the Zairanyas pharmaceutical arm is a significant step forward for Zairas economy, its people, and the country,” he said.

In 2015, Zairawi announced plans to establish a $1 trillion health sector.

Zaidan Dauzem, president of the Zaidans National Council for Health, told Reuters that Zairoa would help Zaire achieve its goal of becoming a global leader in the treatment and management of cancer.

“We are very happy about the government’s decision,” he added.

“Merck is a major player in the Zainan economy and we look forward to the government and the Zaidaans efforts to grow the Zaimaans economy.”